Turning Point’s Modern Oral Ascent: A High-Stakes Pivot With Proof Points
Nicotine pouches reaccelerate to 42% of revenue, but the investment bill is coming due
TPB · Earnings Call · 2026-05-07
Turning Point Brands delivered a quarter that validates its strategic pivot. Modern Oral net sales grew 133% year-over-year, gross sales grew 167%, and the segment now accounts for 42% of consolidated net sales, up from 21% a year ago. CEO Graham Purdy framed the moment as nothing less than a generational shift in how adults consume nicotine:
We believe we are in the midst of a greater than $50 billion generational shift in nicotine consumption, and we are positioning the business to capture meaningful share of nicotine users in this evolving high-barrier category.
That ambition is backed by real distribution momentum. The company secured new wins across critical top chain convenience stores and expects its store count to rise 70% by year end. The freshly expanded TKO partnership—spanning UFC, Zuffa Boxing, and PBR—adds a broad awareness engine. As Summer Frein noted, the company is now investing aggressively in brand building to support future scale: “We secured new wins across critical top chain convenience stores that will expand distribution across our portfolio.” — Summer Frein, Head of Sales or Commercial Executive · 2026-05-07 This is no longer a pilot; it is a full-fledged growth plan with marketing dollars behind it.
The Price of Growth Is Paid Up Front
The reacceleration is not free. Modern Oral’s rise is squeezing near-term profitability as the company front-loads brand building and sales force expansion. Operating income fell 46% year-over-year, and free cash flow swung to -$27.4 million. CFO Andrew Flynn was direct about the investment phase: “First quarter free cash flow was negative $27.4 million, reflective of our investments in trade and brand marketing programs as well as working capital and U.S. manufacturing CapEx.” — Andrew Flynn, Chief Financial Officer · 2026-05-07 Management now guides to full-year EBITDA of $70-$90 million, acknowledging that the year will be a deliberate — and expensive — scaling year for nicotine pouches.
This is a genuine strategic pivot, not a mid-cycle blip. The company is committing $80-$105 million to sales and marketing, including a step-up in marketing investment and retail expansion. As a result, gross margin held at 55%, but operating margin compressed by 11.7 percentage points to 10% in the quarter. The investment is aimed at capturing repeat-purchase consumers and establishing durable share in a nascent category — a high-cost, high-reward thesis.
This Has Been Building for Quarters
What appears new today was already seeded in prior calls. In March, CFO Andrew Flynn prepped investors for the launch of ALP in brick-and-mortar: “We are investing in sales and marketing. And we're also preparing ourselves for the launch of ALP in bricks and mortar in Q2.” — Andrew Flynn, Chief Financial Officer · 2026-03-02 In November, CEO Graham Purdy emphasized the company’s confidence in its portfolio positioning: “We believe we have a winning format as well as two winning brands that give us an opportunity to really chase after consumers.” — Graham Purdy, Chief Executive Officer · 2025-11-05 The current quarter’s chain wins and TKO sponsorship are the execution of those earlier promises — not a surprise announcement.
The keyword trajectory corroborates the company’s own narrative. “nicotine pouch,” “early innings,” and “brand awareness” have been the company’s most prominent themes across the last four quarters, and they all led into this quarter’s acceleration. What’s genuinely new is the scale of confirmed distribution and the breadth of the TKO partnership — a company-unique asset that no other tobacco player in the recent earnings cohort can claim.
The financial trade-off is real but the trajectory is compelling. The company is trading near-term free cash flow for a long-term annuity in a category it believes can reach double-digit share by decade’s end. Operating income dropped to $12 million, down 46% year-over-year, while the company’s gross margin held steady at 55% — the clearest evidence that the profit decline is due to deliberate go-to-market spending rather than product economics. The bet is that the same $80-$105 million of sales and marketing investment will translate into repeat customers and shelf space that compound for years.
Turning Point’s stock has pulled back hard from its February peak, but it has flattened over the last 90 days — suggesting the market is waiting to see whether the growth can outrun the spending. The quarter’s guidance raise on Modern Oral, up to $280-300 million gross sales midpoint, gives investors a clearer target. If the chain wins convert as management expects, this is a story of a mid-cap tobacco company transforming itself into a modern oral leader — with the financial pain of the transition now fully visible.